UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of: November 2025
Commission
File Number: 001-39152
| Quantum Biopharma Ltd.
|
| (Translation of registrant’s name into English) |
1
Adelaide Street East, Suite 801
Toronto,
Ontario M5C 2V9
(Address of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
INCORPORATION
BY REFERENCE
This Report on Form 6-K
and the exhibits attached hereto (Exhibit 99.1 and 99.2) are incorporated by reference into the Registrant’s Registration Statement
on Form F-3 (SEC File No. 333-276264), including any prospectuses forming a part of
such Registration Statement and to be a part thereof from the date on which this report is furnished, to the extent not superseded by
documents or reports subsequently filed or furnished.
CONTENTS
This Report of Foreign
Private Issuer on Form 6-K (this “Form 6-K”) consists of Quantum BioPharma Ltd.’s (i) Unaudited Condensed Consolidated
Financial Statements as of, and for the three and nine months ended September 30, 2025 and 2024, which are attached hereto as Exhibit
99.1; and (ii) Management’s Discussion and Analysis of Financial Condition and Results of Operations for the three and nine months
ended September 30, 2025 and 2024 , which is attached hereto as Exhibit 99.2.
EXHIBIT
INDEX
| Exhibit |
|
Description |
| |
|
|
| 99.1 |
|
Condensed consolidated interim financial statements for the three and nine months ended September 30, 2025 and 2024 |
| |
|
|
| 99.2 |
|
Management’s Discussion and Analysis of Financial Condition and
Results of Operation for the three and nine months ended September 30, 2025 and 2024 |
| |
|
|
| 99.3 |
|
CEO Certificate |
| |
|
|
| 99.4 |
|
CFO Certificate |
| |
|
|
| 101.INS |
|
XBRL Instance Document |
| |
|
|
| 101.SCH |
|
Inline XBRL Taxonomy Extension Schema Document |
| |
|
|
| 101.SCH |
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| |
|
|
| 101.DEF |
|
Inline XBRL Taxonomy Extension Definition Linkbase Document |
| |
|
|
| 101.LAB |
|
Inline XBRL Taxonomy Extension Label Linkbase Document |
| |
|
|
| 101.PRE |
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| |
|
|
| 104 |
|
Cover Page Interactive Data File( formatted as Inline XBRL and contained in Exhibit 101) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
Quantum
Biopharma Ltd.
(Registrant) |
| |
|
|
| Date:
November 6, 2025 |
By: |
/s/
Donal Carroll |
| |
|
Donal
Carroll,
Chief Financial Officer |
